Lung disease associated with orally administered mesalamine for ulcerative colitis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 1582327.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pulmonary symptoms, bilateral interstitial infiltrates and gas exchange abnormalities developed in a patient with ulcerative colitis treated with orally administered mesalamine. Improvement of symptoms and objective findings occurred after drug discontinuation. To the best of our knowledge, this is the first report of lung toxicity associated with orally administered mesalamine.
Medical subject headings
- Aminosalicylic Acids
- Colitis, Ulcerative
- Lung Diseases